Pharmacologic Approaches to Suicide Prevention.

Focus (American Psychiatric Publishing) Pub Date : 2023-04-01 Epub Date: 2023-04-14 DOI:10.1176/appi.focus.20220076
Sidney Zisook, Isabel Domingues, Jason Compton
{"title":"Pharmacologic Approaches to Suicide Prevention.","authors":"Sidney Zisook, Isabel Domingues, Jason Compton","doi":"10.1176/appi.focus.20220076","DOIUrl":null,"url":null,"abstract":"<p><p>Suicide is a leading cause of death that is often preventable. This article reviews the role of medications in treating suicidal behavior and in preventing suicide. For an acute suicidal crisis, ketamine, and perhaps esketamine, are emerging as important tools. For patients with chronic suicidality, clozapine remains the only U.S. Food and Drug Administration (FDA) approved antisuicidal medication, and its use is predominantly for patients with schizophrenia and schizoaffective disorder. An abundance of literature supports the use of lithium among patients with mood disorders, including those with major depressive disorder. Despite the black box warning regarding antidepressants and suicide risk among children, adolescents, and young adults, antidepressants are widely used and remain helpful in reducing suicidal thoughts and behaviors, primarily among patients with mood disorders. Treatment guidelines focus on the importance of optimizing treatment of the psychiatric conditions known to be associated with suicide risk. For patients with these conditions, the authors recommend focusing on suicide as an independent treatment target and using an enhanced medication management strategy that includes maintaining a supportive, nonjudgmental therapeutic relationship; flexibility; collaboration; measurement-based care; consideration of combining medications with nonpharmacologic, evidence-based strategies; and ongoing safety planning.</p>","PeriodicalId":73036,"journal":{"name":"Focus (American Psychiatric Publishing)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172553/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Focus (American Psychiatric Publishing)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1176/appi.focus.20220076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Suicide is a leading cause of death that is often preventable. This article reviews the role of medications in treating suicidal behavior and in preventing suicide. For an acute suicidal crisis, ketamine, and perhaps esketamine, are emerging as important tools. For patients with chronic suicidality, clozapine remains the only U.S. Food and Drug Administration (FDA) approved antisuicidal medication, and its use is predominantly for patients with schizophrenia and schizoaffective disorder. An abundance of literature supports the use of lithium among patients with mood disorders, including those with major depressive disorder. Despite the black box warning regarding antidepressants and suicide risk among children, adolescents, and young adults, antidepressants are widely used and remain helpful in reducing suicidal thoughts and behaviors, primarily among patients with mood disorders. Treatment guidelines focus on the importance of optimizing treatment of the psychiatric conditions known to be associated with suicide risk. For patients with these conditions, the authors recommend focusing on suicide as an independent treatment target and using an enhanced medication management strategy that includes maintaining a supportive, nonjudgmental therapeutic relationship; flexibility; collaboration; measurement-based care; consideration of combining medications with nonpharmacologic, evidence-based strategies; and ongoing safety planning.

预防自杀的药物疗法。
自杀是导致死亡的主要原因之一,而这通常是可以预防的。本文回顾了药物在治疗自杀行为和预防自杀方面的作用。对于急性自杀危机,氯胺酮,或许还有艾司氯胺酮,正在成为重要的工具。对于有慢性自杀倾向的患者,氯氮平仍然是美国食品和药物管理局(FDA)批准的唯一一种抗自杀药物,主要用于精神分裂症和分裂情感障碍患者。大量文献支持在情绪障碍患者(包括重度抑郁障碍患者)中使用锂盐。尽管关于抗抑郁药和儿童、青少年及年轻成年人自杀风险的黑框警告,抗抑郁药仍被广泛使用,并有助于减少自杀想法和行为,主要是在情绪障碍患者中。治疗指南着重强调了优化治疗已知与自杀风险相关的精神疾病的重要性。对于患有这些疾病的患者,作者建议将自杀作为一个独立的治疗目标,并采用强化的药物管理策略,其中包括保持支持性的、非评判性的治疗关系;灵活性;协作;基于测量的护理;考虑将药物与非药物的循证策略相结合;以及持续的安全规划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信